FOLD Amicus Therapeutics Inc.

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.

  • Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ET
  • Jefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT

A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at .

Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednesday, November 13, 2024.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at , and follow on and .

CONTACT:

Investors:

Amicus Therapeutics

Andrew Faughnan

Vice President, Investor Relations



(609) 662-3809

Media:

Amicus Therapeutics

Diana Moore

Head of Global Corporate Affairs and Communications

(609) 662-5079

FOLD–G



EN
01/11/2024

Underlying

FOLDAmicus Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amicus Therapeutics Inc.

 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and...

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

November 6, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Present at Upcoming Investor Conferences in Nov...

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ETJefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT A live audio webcast of each presentation can also be accessed via the investors section of ...

November 1, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results o...

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access...

October 28, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Pat...

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 PRINCETON, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it has entered into a License Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic vers...

October 17, 2024 1 EN
 PRESS RELEASE
Free
FOLD Amicus Therapeu...

Amicus Therapeutics Announces Participation at the World Muscle Societ...

Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the being held October 8-12, 2024 in Prague, Czechia. Poster Session: Pompe Disease Abstract Title: Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa (Poster #657P) Presenter: Barry J. Byrne, MD, PhD, University of Flori...

October 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch